We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
- Authors
Dumitru, Adrian; Dobrica, Elena-Codruta; Croitoru, Adina; Cretoiu, Sanda Maria; Gaspar, Bogdan Severus
- Abstract
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence of a high number of intra tumor infiltrating lymphocytes (TILs). Therefore, immunomodulation is considered to have an important role in cancer treatment, and immune checkpoint inhibitors may be useful for restoring T cell-mediated antitumor immunity. However, the data presented in the literature until now are not sufficient to allow for the identification and selection of patients who really respond to immunotherapy among those with ovarian cancer. Although there are some studies with favorable results, more prospective trials are needed in this sense. This review focuses on the current and future perspectives of PD-1/L1 blockade in ovarian cancer and analyzes the most important immune checkpoint inhibitors used, with the aim of achieving optimal clinical outcomes. Future studies and trials are needed to maximize the efficacy of immune checkpoint blockade therapy in ovarian cancer, as well as in all cancers, in general.
- Subjects
PROGRAMMED cell death 1 receptors; OVARIAN cancer; PROGRAMMED death-ligand 1; TUMOR-infiltrating immune cells; IMMUNE checkpoint inhibitors; IMMUNE checkpoint proteins
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 20, p12067
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms232012067